RT Journal Article
SR Electronic
T1 Synthetic Retinoid Fenretinide Is Effective against a Human Ovarian Carcinoma Xenograft and Potentiates Cisplatin Activity
JF Cancer Research
JO Cancer Res
FD American Association for Cancer Research
SP 5374
OP 5376
VO 53
IS 22
A1 Formelli, Franca
A1 Cleris, Loredana
YR 1993
UL http://cancerres.aacrjournals.org/content/53/22/5374.abstract
AB Fenretinide or N-(4-hydroxyphenyl) retinamide (4HPR) is a synthetic retinoid currently being tested clinically, which can inhibit the development and the growth of breast and prostate cancers in rodents. The efficacy of 4HPR alone and in combination with cisplatin was tested against the human ovarian carcinoma IGROV-1 xenograft i.p. Administration p.o. of 4HPR was not effective, whereas intracavitary treatment significantly increased the survival time of treated mice. It also enhanced the antitumor activity of cisplatin. These findings suggest that 4HPR may be an active agent against epithelial ovarian tumors. ©1993 American Association for Cancer Research.